A
66.37
1.09 (1.67%)
| Previous Close | 65.28 |
| Open | 65.10 |
| Volume | 348,239 |
| Avg. Volume (3M) | 467,612 |
| Market Cap | 3,567,766,016 |
| Price / Sales | 29.89 |
| Price / Book | 9.38 |
| 52 Weeks Range |
| Profit Margin | -37.23% |
| Operating Margin (TTM) | -127.79% |
| Diluted EPS (TTM) | -1.04 |
| Quarterly Revenue Growth (YOY) | 91.50% |
| Total Debt/Equity (MRQ) | 15.25% |
| Current Ratio (MRQ) | 6.01 |
| Operating Cash Flow (TTM) | -20.01 M |
| Levered Free Cash Flow (TTM) | -32.63 M |
| Return on Assets (TTM) | -7.43% |
| Return on Equity (TTM) | -13.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Arcellx, Inc. | Bullish | Bullish |
Stockmoo Score
1.2
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | 2.0 |
| Average | 1.20 |
|
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 12.75% |
| % Held by Institutions | 95.55% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sr One Capital Management, Lp | 30 Jun 2024 | 2,346,630 |
| Cormorant Asset Management, Lp | 30 Jun 2024 | 1,525,000 |
| Suvretta Capital Management, Llc | 30 Jun 2024 | 1,516,254 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 122.00 (Stifel, 83.82%) | Buy |
| Median | 115.00 (73.27%) | |
| Low | 96.00 (Needham, 44.64%) | Buy |
| Average | 111.00 (67.24%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 94.20 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 22 Oct 2024 | 96.00 (44.64%) | Buy | 90.46 |
| 09 Aug 2024 | 81.00 (22.04%) | Buy | 59.05 | |
| Stifel | 18 Oct 2024 | 122.00 (83.82%) | Buy | 96.86 |
| Canaccord Genuity | 17 Oct 2024 | 115.00 (73.27%) | Buy | 95.27 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PATEL KAVITA | - | 90.46 | -1,500 | -135,690 |
| Aggregate Net Quantity | -1,500 | |||
| Aggregate Net Value ($) | -135,690 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 90.46 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PATEL KAVITA | Director | 22 Oct 2024 | Automatic sell (-) | 1,500 | 90.46 | 135,690 |
| PATEL KAVITA | Director | 22 Oct 2024 | Option execute | 1,500 | - | - |
| Date | Type | Details |
|---|---|---|
| 08 Aug 2024 | Announcement | Arcellx Provides Second Quarter 2024 Financial Results and Business Updates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |